Skip to main content

General Rheumatology

Dr. John Cush
@RheumNow
Which ACR 2026 findings will you take back to clinic? Join us Monday, November 16 through Friday, November 20 for RheumNow’s ACR 2026 Topic Panel Recaps. Each panel streams live at 7 PM ET / 6 PM CT / 4 PM PT. Watch live on X, YouTube, LinkedIn, or Facebook. All five panels https://t.co/RbWjwNgljY
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/EkudaG7YiY
Dr. John Cush
@RheumNow
Why Did the Last Drug Fail? When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes https://t.co/r5mQjI79iQ
Dr. John Cush
@RheumNow
One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO
Dr. John Cush
@RheumNow
Scary IPAF IPAF describes patients who have ILD plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease. The 2015 ERS/ATS criteria proposed IPAF as a research classification, not a distinct disease, https://t.co/v3ir4IHia7
anita
@docdhanrajani
Final #ACR2026 post (maybe? 😄)! Huge shoutout to @RheumNow and the incredible team for their phenomenal work in rheumatology education! Can’t believe it took me this long to collaborate with them, but I have a feeling this is the beginning of a long-term relationship! 🙌
anita
@docdhanrajani
@RheumNow #1! 🌍 Global pediatric rheumatology workforce challenges! A survey across 32 countries found 40% lacked in-country training programs. Variable accreditation, limited funding & poor specialty awareness remain key barriers. Abstract 1483. #ACR2026
Adela Castro
@AdelaCastro222
Is it the treatment or the disease? -Multiple meds can cause SCLE: more widespread, EM,Bullous features. -Dupilumab can cause enthesitis: if severe needs dc of medication -Anti-CD 20 may cause IBD (Crohn’s-Like) Great lecture from @md_chawla on Drug induced syndromes #ACR26 https://t.co/EEQL7QNtWC
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, AI and documentation: errors on all five AI platforms tested against guidelines, and cDAPSA documented in 4.9% of PsA records @rheumnow #ACR26 Abstract#0869 Abstract#1348
anita
@docdhanrajani
@RheumNow #2. Abstract 1876. A consensus-driven core outcome set for healthcare transition in adolescents and young adults with JIA identifies 10 outcomes spanning the Quadruple Aim framework: Population health, experience of care, cost of care, provider experience. #ACR2026
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, diagnosis and classification: lower sensitivity of the 2025 ASAS SPARTAN criteria in early axSpA, and a 28 month reduction in diagnostic delay with an integrated referral pathway. @rheumnow #ACR26 Abstract#2347 Abstract#2540
Antoni Chan MD (Prof)
@synovialjoints
Reflection on sequencing: antibody status and patient factors predicted outcome more than mechanism, TNFi cycling was the most common switch in the last 2 decades, and Leeds data suggest some treatment failure may be iatrogenic. @rheumnow #ACR26 Abstract#2284 Abstract#1324
Antoni Chan MD (Prof)
@synovialjoints
Sadhak Sengupta
@sadhaksengupta
@Aclockworkolive @drdavidliew @NEJM @RheumNow Both rap-cel and zola-cel targets to keep the infusion material enriched in CCR7+CD27+ naive state, for which the ex vivo part of the expansion has to be stopped before the cells start differentiating. Longer the ex vivo culture, higher the percentage of differentiation.
Daric Mueller, PA-C
@rheumPAC
Points to consider to D2M AxSpA Mimics + Interfering Factors: Nociplastic Pain Degenerative Joint/Spine/SI/Hip disease Fracture Infection Malignancy Mental/psychosocial factors Poor sleep Other (crystalline arthritis, metabolic bone disease) Abst2944 #ACR26 @RheumNow
Dr. John Cush
@RheumNow
Reading the Sacroiliac Joint Early: What MRI Reveals in axSpA Imaging is one of the best tools for catching axSpA sooner, and the 2025 ASAS-SPARTAN revised classification criteria reflect that: the most heavily weighted variable is “MRI indicative of axSpA in the sacroiliac https://t.co/wEcLN8Vq9r
Antoni Chan MD (Prof)
@synovialjoints
In the ALLIANCE randomised trial, 82 physicians worked through three rheumatology vignettes with or without a certified large language model decision support system. The decision support system alone reached 33.3% top diagnosis accuracy against 27.0% for unassisted
×